Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Sökning: WFRF:(Wiklund H.) > (2000-2004) > Phase 2 study of al...

LIBRIS Formathandbok (Information om MARC21)

Fältnamn	Indikatorer	Metadata
000		04177naa a2200493 4500
001		oai:DiVA.org:liu-47796
003		SwePub
008		091011s2003 \| \|\|\|\|\|\|\|\|\|\|\|000 \|\|eng\|
009		oai:lup.lub.lu.se:7424fa58-7098-4bf9-9300-9e7eccc7cd8f
009		oai:prod.swepub.kib.ki.se:1952232
024	7	a https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-477962 URI
024	7	a https://doi.org/10.1182/blood-2002-09-28022 DOI
024	7	a https://lup.lub.lu.se/record/3107322 URI
024	7	a http://kipublications.ki.se/Default.aspx?queryparsed=id:19522322 URI
040		a (SwePub)liud (SwePub)lud (SwePub)ki
041		a engb eng
042		9 SwePub
072	7	a ref2 swepub-contenttype
072	7	a art2 swepub-publicationtype
100	1	a Lundin, Ju Karolinska Institutet4 aut
245	1 0	a Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome
264	1	b American Society of Hematology,c 2003
338		a print2 rdacarrier
520		a This phase 2 study evaluated the safety and efficacy of alemtuzumab in 22 patients with advanced mycosis fungoides/Sezary syndrome (MF/SS). Most patients had stage III or IV disease, reduced performance status, and severe itching. The overall response (OR) rate was 55%, with 32% of patients in complete remission (CR) and M in, partial remission (PR). Sezary cells were cleared from the blood in 6 of 7 (86%) patients, and CR in lymph nodes was observed in 6 of 11 (55%) patients. The effect was better on erythro-derma (OR, 69%) than on plaque or skin tumors (OR, 40%) and in patients who had received 1 to 2 previous regimens (OR, 80%) thin in those who had received 3 or more prior regimens (OR, 33%). Itching, self-assessed on a 0 to 10 visual analog scale, was reduced from a median of 8 before treatment to 2 at end. of therapy. Median time to treatment failure was 12 months (range, 5-32+ months). Cytomegalovirus (CMV), reactivation (causing fever without pneumonitis and responding to ganciclovir) occurred in 4 (18%) patients. Six additional patients had suspect or manifest infection (fever of unknown origin, 3, generalized herpes simplex, 1, fatal aspergillosis, 1). One patient had fatal Mycobacterium pneumonia at 10+ months. All serious infectious adverse events (except CMV) occurred in patients who had received 3 or more prior regimens. Progression of squamous cell skin carcinoma was noted in 1 patient. Alemtuzumab shows promising clinical activity and an acceptable safety profile in patients with advanced MF/SS, particularly in patients with erythroderma and severe itching and those who were not heavily pretreated. (C) 2003 by The American Society of Hematology.
650	7	a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Hematologi0 (SwePub)302022 hsv//swe
650	7	a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Hematology0 (SwePub)302022 hsv//eng
653		a MEDICINE
653		a MEDICIN
700	1	a Hagberg, H4 aut
700	1	a Repp, R4 aut
700	1	a Cavallin-Ståhl, Evau Lund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)onk-ecs
700	1	a Freden, S4 aut
700	1	a Juliusson, Gunnaru Östergötlands Läns Landsting,Linköpings universitet,Hälsouniversitetet,Onkologi,Hematologiska kliniken US4 aut0 (Swepub:liu)gunju78
700	1	a Rosenblad, E4 aut
700	1	a Tjonnfjord, G4 aut
700	1	a Wiklund, T4 aut
700	1	a Osterborg, Au Karolinska Institutet4 aut
710	2	a Karolinska Institutetb Bröstcancer-genetik4 org
773	0	t Bloodd : American Society of Hematologyg 101:11, s. 4267-4272q 101:11<4267-4272x 0006-4971x 1528-0020
856	4	u http://dx.doi.org/10.1182/blood-2002-09-2802x freey FULLTEXT
856	4 8	u https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-47796
856	4 8	u https://doi.org/10.1182/blood-2002-09-2802
856	4 8	u https://lup.lub.lu.se/record/310732
856	4 8	u http://kipublications.ki.se/Default.aspx?queryparsed=id:1952232

Hitta via bibliotek

Blood (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

Hitta mer i SwePub

Av författaren/redakt...: Lundin, J; Hagberg, H; Repp, R; Cavallin-Ståhl, ...; Freden, S; Juliusson, Gunna ...; visa fler...; Rosenblad, E; Tjonnfjord, G; Wiklund, T; Osterborg, A; visa färre...

Om ämnet

MEDICIN OCH HÄLSOVETENSKAP: MEDICIN OCH HÄLS ...; och Klinisk medicin; och Hematologi

Artiklar i publikationen: Blood

Av lärosätet: Linköpings universitet; Lunds universitet; Karolinska Institutet

Sök utanför SwePub

Sök vidare i:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se